The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Bulletin of the Hospital for Joint Diseases

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 28902599PMCID PMC7010333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).

  2016cited by this paper
• Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

  2016cited by this paper
• CTLA-4 and PD-1 Pathways

  2016cited by this paper
• Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.

  2016cited by this paper
• Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

  2016cited by this paper
• Stress-related skin disorders

  2016cited by this paper
• Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

  2016cited by this paper
• Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis

  2015cited by this paper
• Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells

  2015cited by this paper
• Tim-3 and Tim-4 as the potential targets for antitumor therapy

  2015cited by this paper
• The immunogenetics of Psoriasis: A comprehensive review.

  2015cited by this paper
• Regulation of T cell responses by the receptor molecule Tim-3

  2014cited by this paper
• Expression of programmed death‐1 in skin biopsies of benign inflammatory vs. lymphomatous erythroderma

  2014cited by this paper
• Psoriatic arthritis: current therapy and future directions

  2013cited by this paper
• Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

  2013cited by this paper
• CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance.

  2013cited by this paper
• Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity.

  2013cited by this paper
• Psoriasis and its comorbidities.

  2012cited by this paper
• The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin‐9/tim‐3 pathway

  2012cited by this paper
• Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion

  2012cited by this paper
• Blockade of Tim‐3 signaling restores the virus‐specific CD8+ T‐cell response in patients with chronic hepatitis B

  2012cited by this paper
• Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis.

  2012cited by this paper
• FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis

  2012cited by this paper
• Tim-3, a negative regulator of anti-tumor immunity.

  2012cited by this paper
• Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

  2011cited by this paper
• The CD4-like molecule LAG-3, biology and therapeutic applications

  2011cited by this paper
• The Influence of Stress on the Development and Severity of Immune-Mediated Diseases

  2011cited by this paper
• A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection

  2010cited by this paper
• The PD‐1 pathway in tolerance and autoimmunity

  2010cited by this paper
• TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity

  2010cited by this paper
• Psoriasis

  2010cited by this paper
• 8-Methoxypsoralen Plus Ultraviolet A Therapy Acts via Inhibition of the IL-23/Th17 Axis and Induction of Foxp3+ Regulatory T Cells Involving CTLA4 Signaling in a Psoriasis-Like Skin Disorder

  2010cited by this paper
• CD28 and CTLA‐4 coreceptor expression and signal transduction

  2009cited by this paper
• Role of Tim-3/Galectin-9 Inhibitory Interaction in Viral-Induced Immunopathology: Shifting the Balance toward Regulators1

  2009cited by this paper
• LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1

  2009cited by this paper
• Yin–Yang of costimulation: crucial controls of immune tolerance and function

  2009cited by this paper
• PD‐1 signaling in primary T cells

  2009cited by this paper
• TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines

  2009cited by this paper
• Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation.

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• The role of CTLA-4 in immune regulation

  2008cited by this paper
• Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis.

  2008cited by this paper
• The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

  2007cited by this paper
• Proliferation of activated CD1d‐restricted NKT cells is down‐modulated by lymphocyte activation gene‐3 signaling via cell cycle arrest in S phase

  2007cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

  2007cited by this paper
• CTLA‐4 gene polymorphisms and natural soluble CTLA‐4 protein in psoriasis vulgaris

  2006cited by this paper
• T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor.

  2006cited by this paper
• The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

  2005cited by this paper
• Expression of lymphocyte activation gene 3 (LAG‐3) on B cells is induced by T cells

  2005cited by this paper
• Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation1

  2005cited by this paper
• The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells

  2005cited by this paper
• Structural and functional analysis of the costimulatory receptor programmed death-1.

  2004cited by this paper
• Role of LAG-3 in regulatory T cells.

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• No associations of CTLA-4 and ICAM-1 polymorphisms with psoriasis in the Korean population.

  2003cited by this paper
• Cytotoxic T lymphocyte antigen-4 gene (CTLA4) polymorphisms in Japanese patients with psoriasis vulgaris.

  2003cited by this paper
• Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis.

  2002cited by this paper
• Phenotypic analysis of the murine CD4‐related glycoprotein, CD223 (LAG‐3)

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.

  2002cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry.

  2000cited by this paper
• Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte–Associated Antigen 4–Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells

  2000cited by this paper
• Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4

  2000cited by this paper
• LAG-3 does not define a specific mode of natural killing in human.

  1998cited by this paper
• Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein.

  1997cited by this paper
• Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2.

  1997cited by this paper
• Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.

  1997cited by this paper
• Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

  1997cited by this paper
• Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation.

  1997cited by this paper
• Regulation of CTLA-4 expression during T cell activation.

  1996cited by this paper
• Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

  1996cited by this paper
• Expression and function of CD80 and CD86 costimulator molecules on synovial dendritic cells in chronic arthritis.

  1996cited by this paper
• Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

  1996cited by this paper
• Cytotoxic T Lymphocyte-associated Molecule-4, a High Avidity Receptor for CD80 and CD86, Contains an Intracellular Localization Motif in Its Cytoplasmic Tail (*)

  1995cited by this paper
• Clinical, Cosmetic and Investigational Dermatology Dovepress Psoriasis and Comorbidities: Links and Risks

  year unknowncited by this paper

• Transcriptomic landscape of generalized pustular psoriasis before and after acitretin/glucocorticoids treatment

  2025cites this paper
• Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma

  2021cites this paper
• Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.

  2021cites this paper